EMA's CHMP recommends approval of Cystadrops (mercaptamine) for cystinosis- Orphan Europe
The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Cystadrops (mercaptamine), from Orphan Europe, intended for the treatment of corneal cystine crystal deposits in patients with cystinosis.
Cystadrops is indicated for the treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis. The benefit of Cystadrops is its ability to reduce corneal cystine crystal accumulation. The most common side effects are eye pain, ocular hyperaemia, eye pruritus, increased lacrimation, blurred vision and eye irritation.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins